samedan logo
 
 
 
spacer
home > ebr > winter 2002 > from genes to drugs
PUBLICATIONS
European Biopharmaceutical Review

From Genes to Drugs

One of the biggest obstacles in the development of cancer therapeutics is the sheer complexity of the problem. Cancer may result from a large number of genetic and molecular defects, or combination of these defects, giving rise to loss of cell cycle checkpoints and unregulated cell division. Even individual tumours may exhibit heterogeneous phenotypes at the cellular level. The inherent genetic instability of cancer cells may also add to the problem, enabling them to continue to change during treatment and effectively presenting a moving target.The majority of anti-cancer therapeutics currently in use were discovered due to their ability to kill fast-growing cancer cells. Unfortunately, these often cause severe side effects due to their impact on other fast-growing cells in the body. There is, therefore, a need to design drugs that target a specific pathogenic pathway and to base the design of the drug upon the structure of its protein target.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Bob Jackson, Executive Director of R&D at Cyclacel Dr Robert Jackson joined Cyclacel in January 2001. Prior to this he was Research and Development Director at Celltech Group plc and Executive Director, R&D and Chief Operating Officer at Chiroscience Group plc.
Before these appointments, Dr Jackson was Vice President of R&D at Agouron Pharmaceuticals and headed cancer research at DuPont Pharmaceuticals and Warner-Lambert Company. Dr Jackson has been instrumental in the discovery and development of several marketed drugs used to treat cancer, HIV and other serious diseases. He holds a BA from the University of Cambridge and a PhD from the University of London, Institute of Cancer Research.

spacer
Dr Bob Jackson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019

Ahead of the 2019 HPAPI USA Conference taking place in Boston on 21st 22nd October, SMi caught up with Richard Arnett, Manager, Industrial Hygiene, Pharmascience who is speaking on Day Two of the agenda. Richard shared his thoughts on how the industry has developed and briefly touched on what he will be discussing in October.
More info >>

White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement